正在加速推进狂犬疫苗迭代升级的艾美疫苗,在新品研发上再获新战果。 艾美疫苗11月17日发布公告称,公司自主研发的无血清迭代狂犬病疫苗已于近日向国家药品监督管理局提交上市注册预申请。 艾美疫苗表示,根据已完成揭盲的Ⅲ期临床研究结果显示,公司的无血清迭代狂犬病疫苗具有良好的安全性、免疫原性和免疫持久性,达到临床预设目标。 引领行业创新有望全球首个问世 据公告,狂犬疫苗有两种,一种是有血清狂犬...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.